ALPHA DNA Investment Management

Alex Tsigdinos serves as Founder and Chief Investment Officer and holds final authority over portfolio construction and risk limits. His prior experience includes portfolio management at Gotham Asset Management, where he worked on systematic long/short equity strategies before transitioning to global macro. The investment team is deliberately small, combining quantitative researchers with Tsigdinos' macro overlay.

Alpha DNA blends both approaches. Machine learning models generate the core trade signals — identifying regime shifts, relative value, and trend across rates, FX, equity indices, and commodities — but Tsigdinos retains discretionary override on position sizing and tail-risk scenarios. The firm describes this as 'machine-driven, human-supervised' rather than fully automated execution.

The firm trades liquid global macro instruments: G10 and emerging-market currencies via FX forwards and futures, sovereign interest-rate futures and bonds, major equity-index futures, and commodity futures including energy and metals. The strategy avoids illiquid private markets and single-name equities, focusing entirely on instruments with deep central-limit order book liquidity.

Tsigdinos recruits from graduate programs in computer science, statistics, and operations research, prioritizing experience with TensorFlow, PyTorch, and reinforcement learning frameworks over traditional finance backgrounds. Recent job postings (per LinkedIn, January 2024) emphasize deep reinforcement learning for autonomous trading, signaling a shift toward agent-based models that learn trade execution independently.

The firm operates a commingled master fund structure, domiciled in Delaware as a limited partnership, with a feeder fund available for offshore investors (per SEC filings, Form D, 2020). There is no public record of separately managed accounts, though the exempt reporting structure permits flexibility for institutional managed accounts if demand arises.

Based on standard industry practice for emerging quantitative macro managers, Alpha DNA likely charges a management fee of 1.5% to 2% and a performance allocation of 20%, though specific terms have not been publicly disclosed. Early-stage funds of this size often negotiate bespoke fees with anchor investors, so precise numbers may vary by commitment date and size.

The firm has raised external capital, evidenced by its SEC Form D filings for a pooled investment fund (first filed 2020). Given the estimated AUM band of $150 million to $500 million and the expenses of maintaining prime brokerage relationships with major banks, the capital base likely combines founder commitment with external limited partner capital from family offices and fund-of-funds, though specific investor identities remain private.